Epidermal growth factor-induced GnRH-II synthesis contributes to ovarian cancer cell invasion

Molecular Endocrinology

Volumn 23, Issue 10, 2009, Pages 1646-1656

  Song, Ling Poon ^a   Hammond, Gareth T ^a   Leung, Peter C K ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CCAAT ENHANCER BINDING PROTEIN BETA; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; EPIDERMAL GROWTH FACTOR; GONADORELIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CARCINOMA CELL; CELL ACTIVITY; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DEPLETION; DOSE RESPONSE; ENHANCER REGION; FEMALE; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; MUTAGENESIS; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION;

CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL LINE, TUMOR; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GONADOTROPIN-RELEASING HORMONE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, BIOLOGICAL; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTEIN BINDING; RESPONSE ELEMENTS; RNA, MESSENGER;

EID: 70349780642     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2009-0147     Document Type: Article

References (52)

1. Choi JH, Gilks CB, Auersperg N, Leung PC 2006 Immunolocalization of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and type I GnRH receptor during follicular development in the human ovary. J Clin Endocrinol Metab 91:4562-4570 (Pubitemid 44833439)
2. Gründker C, Schlotawa L, Viereck V, Eicke N, Horst A, Kairies B, Emons G 2004 Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor. Eur J Endocrinol 151:141-149 (Pubitemid 39117377)
3. Gründker C, Günthert AR, Millar RP, Emons G 2002 Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J Clin Endocrinol Metab 87:1427-1430 (Pubitemid 36121120)
4. Kim KY, Choi KC, Auersperg N, Leung PC 2006 Mechanism of gonadotropin-releasing hormone (GnRH)-I and -II-induced cell growth inhibition in ovarian cancer cells: role of the GnRH-I receptor and protein kinase C pathway. Endocr Relat Cancer 13:211-220
5. Cheung LW, Leung PC, Wong AS 2006 Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9. Cancer Res 66:10902-10910
6. Chen CL, Cheung LW, Lau MT, Choi JH, Auersperg N, Wang HS, Wong AS, Leung PC 2007 Differential role of gonadotropin-releasing hormone on human ovarian epithelial cancer cell invasion. Endocrine 31:311-320 (Pubitemid 47574986)
7. Poon SL, An BS, So WK, Hammond GL, Leung PC 2008 Temporal recruitment of transcription factors at the 3′,5′-cyclic adenosine 5′-monophosphate-response element of the human GnRH-II promoter. Endocrinology 149:5162-5171
8. Cheng CK, Hoo RL, Chow BK, Leung PC 2003 Functional cooperation between multiple regulatory elements in the untranslated exon 1 stimulates the basal transcription of the human GnRH-II gene. Mol Endocrinol 17:1175-1191
9. Hoo RL, Chan KY, Leung FK, Lee LT, Leung PC, Chow BK 2007 Involvement of NF-κB subunit p65 and retinoic acid receptors, RARα and RXRα, in transcriptional regulation of the human GnRH II gene. FEBS J 274:2695-2706
10. Casamassimi A, De Luca A, Agrawal S, Stromberg K, Salomon DS, Normanno N 2000 EGF-related antisense oligonucleotides inhibit the proliferation of human ovarian carcinoma cells. Ann Oncol 11:319-325 (Pubitemid 30214670)
11. Lafky JM, Wilken JA, Baron AT, Maihle NJ 2008 Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta 1785:232-265
12. Yarden Y, Schlessinger J 1987 Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry 26:1443-1451 (Pubitemid 17045875)
13. Yarden Y, Schlessinger J 1987 Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation. Biochemistry 26:1434-1442 (Pubitemid 17045874)
14. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y 1996 A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16:5276-5287 (Pubitemid 26315047)
15. Honegger AM, Kris RM, Ullrich A, Schlessinger J 1989 Evidence that autophosphorylation of solubilized receptors for epidermal growth factor is mediated by intermolecular cross-phosphorylation. Proc Natl Acad Sci USA 86:925-929 (Pubitemid 19056264)
16. Ahmed N, Maines-Bandiera S, Quinn MA, Unger WG, Dedhar S, Auersperg N 2006 Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium. Am J Physiol Cell Physiol 290:C1532-C1542 (Pubitemid 43830793)
17. Klapper LN, Kirschbaum MH, Sela M, Yarden Y 2000 Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 77:25-79 (Pubitemid 29439302)
18. McClellan M, Kievit P, Auersperg N, Rodland K 1999 Regulation of proliferation and apoptosis by epidermal growth factor and protein kinase C in human ovarian surface epithelial cells. Exp Cell Res 246:471-479 (Pubitemid 29394010)
19. Carter TH, Kung HJ 1994 Tissue-specific transformation by oncogenic mutants of epidermal growth factor receptor. Crit Rev Oncog 5:389-428
20. Salomon DS, Brandt R, Ciardiello F, Normanno N 1995 Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232
21. Psyrri A, Kassar M, Yu Z, Bamias A, Weinberger PM, Markakis S, Kowalski D, Camp RL, Rimm DL, Dimopoulos MA 2005 Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res 11:8637-8643 (Pubitemid 43005911)
22. Lassus H, Sihto H, Leminen A, Joensuu H, Isola J, Nupponen NN, Butzow R 2006 Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med 84:671-681 (Pubitemid 44164262)
23. Schilder RJ, Sill MW, Chen X, Darcy KM, Decesare SL, Lewandowski G, Lee RB, Arciero CA, Wu H, Godwin AK 2005 Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin Cancer Res 11:5539-5548 (Pubitemid 41060831)
24. Shaywitz AJ, Greenberg ME 1999 CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 68:821-861
25. Singh B, Schneider M, Knyazev P, Ullrich A 2009 UV-induced EGFR signal transactivation is dependent on proligand shedding by activated metalloproteases in skin cancer cell lines. Int J Cancer 124:531-539
26. Witters L, Scherle P, Friedman S, Fridman J, Caulder E, Newton R, Lipton A 2008 Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res 68:7083-7089
27. So WK, Cheng JC, Poon SL, Leung PC 2008 Gonadotropin-releasing hormone and ovarian cancer: a functional and mechanistic overview. FEBS J 275:5496-5511
28. Cheung LW, Wong AS 2008 Gonadotropin-releasing hormone: GnRH receptor signaling in extrapituitary tissues. FEBS J 275: 5479-5495
29. Ning Y, Zeineldin R, Liu Y, Rosenberg M, Stack MS, Hudson LG 2005 Down-regulation of integrin α2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation. Cancer Res 65:9280-9286 (Pubitemid 41507994)
30. Li AJ, Scoles DR, Armstrong KU, Karlan BY 2008 Androgen receptor cytosine-adenine-guanine repeat polymorphisms modulate EGFR signaling in epithelial ovarian carcinomas. Gynecol Oncol 109:220-225
31. Kalli KR, Bradley SV, Fuchshuber S, Conover CA 2004 Estrogen receptor-positive human epithelial ovarian carcinoma cells respond to the antitumor drug suramin with increased proliferation: possible insight into ER and epidermal growth factor signaling interactions in ovarian cancer. Gynecol Oncol 94:705-712 (Pubitemid 39194464)
32. RosanòL, Di Castro V, Spinella F, Tortora G, Nicotra MR, Natali PG, Bagnato A 2007 Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. Cancer Res 67:6351-6359 (Pubitemid 47037518)
33. Chinnappan D, Qu X, Xiao D, Ratnasari A, Weber HC 2008 Human gastrin-releasing peptide receptor gene regulation requires transcription factor binding at two distinct CRE sites. Am J Physiol Gastrointest Liver Physiol 295:G153-G162
34. Nomura T, Huang WC, Zhau HE, Wu D, Xie Z, Mimata H, Zayzafoon M, Young AN, Marshall FF, Weitzmann MN, Chung LW 2006 β2-Microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMP-responsive element-binding protein, and vascular endothelial growth factor axis. Clin Cancer Res 12:7294-7305 (Pubitemid 46095401)
35. Pino MS, Nawrocki ST, Cognetti F, Abruzzese JL, Xiong HQ, McConkey DJ 2005 Prostaglandin E2 drives cyclooxygenase-2 expression via cyclic AMP response element activation in human pancreatic cancer cells. Cancer Biol Ther 4:1263-1269
36. Khokhlatchev AV, Canagarajah B, Wilsbacher J, Robinson M, Atkinson M, Goldsmith E, Cobb MH 1998 Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation. Cell 93:605-615 (Pubitemid 28240721)
37. Roberson MS, Ban M, Zhang T, Mulvaney JM 2000 Role of the cyclic AMP response element binding complex and activation of mitogen-activated protein kinases in synergistic activation of the glycoprotein hormone α subunit gene by epidermal growth factor and forskolin. Mol Cell Biol 20:3331-3344 (Pubitemid 30243879)
38. Robinson MJ, Stippec SA, Goldsmith E, White MA, Cobb MH 1998 A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation. Curr Biol 8:1141-1150 (Pubitemid 28494712)
39. Sharma N, Nyborg JK 2008 The coactivators CBP/p300 and the histone chaperone NAP1 promote transcription-independent nucleosome eviction at the HTLV-1 promoter. Proc Natl Acad Sci USA 105:7959-7963 (Pubitemid 351904689)
40. Geiger TR, Sharma N, Kim YM, Nyborg JK 2008 The human T-cell leukemia virus type 1 tax protein confers CBP/p300 recruitment and transcriptional activation properties to phosphorylated CREB. Mol Cell Biol 28:1383-1392 (Pubitemid 351214139)
41. Shuman JD, Sebastian T, Kaldis P, Copeland TD, Zhu S, Smart RC, Johnson PF 2004 Cell cycle-dependent phosphorylation of C/EBPβ mediates oncogenic cooperativity between C/EBPβ and H-RasV12. Mol Cell Biol 24:7380-7391 (Pubitemid 39121468)
42. Sterneck E, Johnson PF 1998 CCAAT/enhancer binding protein β is a neuronal transcriptional regulator activated by nerve growth factor receptor signaling. J Neurochem 70:2424-2433 (Pubitemid 28252368)
43. Cheng CK, Leung PC 2005 Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans. Endocr Rev 26:283-306
44. Chen A, Laskar-Levy O, Ben-Aroya N, Koch Y 2001 Transcriptional regulation of the human GnRH II gene is mediated by a putative cAMP response element. Endocrinology 142:3483-3492 (Pubitemid 32681756)
45. Normanno N, Bianco C, Strizzi L, Mancino M, Maiello MR, De Luca A, Caponigro F, Salomon DS 2005 The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets 6:243-257 (Pubitemid 40667793)
46. Sewell JM, Macleod KG, Ritchie A, Smyth JF, Langdon SP 2002 Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ("Iressa"). Br J Cancer 86:456-462 (Pubitemid 34185133)
47. Stromberg K, Collins 4th TJ, Gordon AW, Jackson CL, Johnson GR 1992 Transforming growth factor-α acts as an autocrine growth factor in ovarian carcinoma cell lines. Cancer Res 52:341-347
48. Chien CH, Chen CH, Lee CY, Chang TC, Chen RJ, Chow SN 2004 Detection of gonadotropin-releasing hormone receptor and its mRNA in primary human epithelial ovarian cancers. Int J Gynecol Cancer 14:451-458 (Pubitemid 38747424)
49. Berns EM, Klijn JG, Henzen-Logmans SC, Rodenburg CJ, van der Burg ME, Foekens JA 1992 Receptors for hormones and growth factors and (onco)-gene amplification in human ovarian cancer. Int J Cancer 52:218-224
50. Brader KR, Wolf JK, Chakrabarty S, Price JE 1998 Epidermal growth factor receptor (EGFR) antisense transfection reduces the expression of EGFR and suppresses the malignant phenotype of a human ovarian cancer cell line. Oncol Rep 5:1269-1274 (Pubitemid 28372601)
51. Alper O, De Santis ML, Stromberg K, Hacker NF, Cho-Chung YS, Salomon DS 2000 Anti-sense suppression of epidermal growth factor receptor expression alters cellular proliferation, cell-adhesion and tumorigenicity in ovarian cancer cells. Int J Cancer 88:566-574 (Pubitemid 30805070)
52. Woo MM, Salamanca CM, Minor A, Auersperg N 2007 An improved assay to quantitate the invasiveness of cells in modified Boyden chambers. In Vitro Cell Dev Biol Anim 43:7-9 (Pubitemid 47087329)